HRP20171590T1 - Polimeri koji vežu protone za oralnu primjenu - Google Patents
Polimeri koji vežu protone za oralnu primjenu Download PDFInfo
- Publication number
- HRP20171590T1 HRP20171590T1 HRP20171590TT HRP20171590T HRP20171590T1 HR P20171590 T1 HRP20171590 T1 HR P20171590T1 HR P20171590T T HRP20171590T T HR P20171590TT HR P20171590 T HRP20171590 T HR P20171590T HR P20171590 T1 HRP20171590 T1 HR P20171590T1
- Authority
- HR
- Croatia
- Prior art keywords
- use according
- pharmaceutical preparation
- independently hydrogen
- residue
- hydrogen
- Prior art date
Links
- 229920000642 polymer Polymers 0.000 title claims 24
- 229910052739 hydrogen Inorganic materials 0.000 claims 33
- 239000001257 hydrogen Substances 0.000 claims 33
- 150000002431 hydrogen Chemical class 0.000 claims 29
- 239000000825 pharmaceutical preparation Substances 0.000 claims 24
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 22
- 150000001412 amines Chemical class 0.000 claims 20
- 125000001931 aliphatic group Chemical group 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 10
- 125000004103 aminoalkyl group Chemical group 0.000 claims 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 9
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 8
- 125000003277 amino group Chemical group 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 7
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 claims 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 6
- 239000000872 buffer Substances 0.000 claims 6
- 208000010444 Acidosis Diseases 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000001188 haloalkyl group Chemical group 0.000 claims 5
- 239000011780 sodium chloride Substances 0.000 claims 5
- 229920002554 vinyl polymer Polymers 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 206010027417 Metabolic acidosis Diseases 0.000 claims 4
- 230000002452 interceptive effect Effects 0.000 claims 4
- 150000002500 ions Chemical class 0.000 claims 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims 3
- 102000006335 Phosphate-Binding Proteins Human genes 0.000 claims 3
- 108010058514 Phosphate-Binding Proteins Proteins 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 3
- 235000019799 monosodium phosphate Nutrition 0.000 claims 3
- 210000002966 serum Anatomy 0.000 claims 3
- 210000000813 small intestine Anatomy 0.000 claims 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims 3
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 2
- 239000012062 aqueous buffer Substances 0.000 claims 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims 2
- 239000008367 deionised water Substances 0.000 claims 2
- 229910021641 deionized water Inorganic materials 0.000 claims 2
- 239000012530 fluid Substances 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 229910052700 potassium Inorganic materials 0.000 claims 2
- 239000011591 potassium Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- 230000008961 swelling Effects 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- MALIONKMKPITBV-UHFFFAOYSA-N 2-(3-chloro-4-hydroxyphenyl)-n-[2-(4-sulfamoylphenyl)ethyl]acetamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1CCNC(=O)CC1=CC=C(O)C(Cl)=C1 MALIONKMKPITBV-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 230000007950 acidosis Effects 0.000 claims 1
- 208000026545 acidosis disease Diseases 0.000 claims 1
- 125000002723 alicyclic group Chemical group 0.000 claims 1
- 125000001589 carboacyl group Chemical group 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000003431 cross linking reagent Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000004404 heteroalkyl group Chemical group 0.000 claims 1
- -1 hydroxy, amino Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 238000006116 polymerization reaction Methods 0.000 claims 1
- 238000010526 radical polymerization reaction Methods 0.000 claims 1
- 229930195734 saturated hydrocarbon Chemical group 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F226/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
- C08F226/02—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
- C08G73/024—Polyamines containing oxygen in the form of ether bonds in the main chain
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/4077—Concentrating samples by other techniques involving separation of suspended solids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/4077—Concentrating samples by other techniques involving separation of suspended solids
- G01N2001/4083—Concentrating samples by other techniques involving separation of suspended solids sedimentation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/4077—Concentrating samples by other techniques involving separation of suspended solids
- G01N2001/4088—Concentrating samples by other techniques involving separation of suspended solids filtration
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Claims (30)
1. Farmaceutski pripravak za upotrebu u postupku liječenja metaboličke acidoze oralnim davanjem navedenog farmaceutskog pripravka, te navedeni pripravak sadrži umreženi aminski polimer koji veže protone koji sadrži aminski ostatak koji odgovara formuli 1:
[image]
naznačen time da
R1, R2 i R3 su neovisno vodik, hidrokarbil, supstituirani hidrokarbil, uz uvjet da je ipak najmanje jedan od R1, R2 i R3 različit od vodika,
umreženi aminski polimer ima ravnotežni omjer bubrenja u deioniziranoj vodi od 5 ili niži; umreženi aminski polimer veže odgovarajući molarni odnos kloridnih iona prema ometajućim ionima od najmanje 0,35:1, u puferu s ometajućim ionima na 37°C pri čemu su ometajući ioni fosfatni ioni i ometajući ionski pufer je otopina na pH 5,5 36mM klorida i 20mM fosfata.
2. Farmaceutski pripravak za upotrebu prema zahtjevu 1, naznačen time da umreženi aminski polimer ima ravnotežni odnos bubrenja u deioniziranoj vodi od 4 ili manji, ili 3 ili manji, ili 2 ili manji, ili 1,5 ili manji, ili 1 ili manji.
3. Farmaceutski pripravak za upotrebu prema bilo kojem od prethodnih zahtjeva naznačen time da su R1, R2 i R3 neovisno vodik, alkil, alkenil, alil, vinil, aril, aminoalkil, alkanol, haloalkil, hidroksialkil, eterski, heteroaril ili heterociklički ostatak uz uvjet da ipak svaki od R1, R2 i R3 nije vodik, ili određenije farmaceutski pripravak za upotrebu prema bilo kojem od prethodnih zahtjeva gdje su R1, R2 i R3 neovisno vodik, alifatski ili heteroalifatski ostatak, međutim najmanje jedan od R1, R2 i R3 je različit od vodika.
4. Farmaceutski pripravak za upotrebu prema bilo kojem od zahtjeva 1-3, naznačen time da umreženi aminski polimer sadrži ostatak amina koji odgovara formuli 1a i umreženi aminski polimer je dobiven radikalnom polimerizacijom amina koji odgovara formuli 1a:
[image]
pri čemu R4 i R5 su neovisno vodik, hidrokarbil ili supstituirani hidrokarbil.
5. Farmaceutski pripravak za upotrebu prema zahtjevu 4, naznačen time da R4 i R5su neovisno vodik, alkil, alkenil, alili, vinil, aril, aminoalkil, alkanol, haloalkil, hidroksialkil, eterski, heteroarilni ili heterociklički ostatak iliodređenije farmaceutska pripravak prema zahtjevu 4, pri čemu R4 i R5 su neovisno vodik, alifatski ili heteroalifatski ostatak.
6. Farmaceutski pripravak za upotrebu prema bilo kojem od zahtjeva 1-3, naznačen time da umreženi aminski polimer sadrži ostatak amina koji odgovara formuli 1b i umreženi aminski polimer je dobiven supstitucijskom polimerizacijom amina koji odgovara formuli 1b s polifunkcionalnim sredstvom za umrežavanje:
[image]
pri čemu R4 i R5 su neovisno vodik, hidrokarbil ili supstituirani hidrokarbil, R6 je alifatski i R61 i R62 su neovisno vodik, alifatski ili heteroalifatski ostatak.
7. Farmaceutski pripravak za upotrebu prema zahtjevu 6, naznačen time da R4 i R5 su neovisno vodik, zasićeni ugljikovodik, nezasićeni alifatski ostatak, aril, heteroaril, heteroalkil ili nezasićeni heteroalifatski ostatak ili specifičnije farmaceutski pripravak prema zahtjevu 6, pri čemu R4i R5 su neovisno vodik, alkil, alkenil, alil, vinil, aril, aminoalkil, alkanol, haloalkil, hidroksialkil, eterski, heteroarilni ili heterociklički ostatak ili određenije farmaceutski pripravak prema zahtjevu 6, pri čemu R4 i R5 su neovisno vodik, alil i aminoalkil.
8. Farmaceutski pripravak za upotrebu prema bilo kojem od zahtjeva u kojima umreženi aminski polimer sadrži ostatak amina koji odgovara formuli 1C:
[image]
naznačen time da R7 je vodik, alifatski ili heteroalifatski ostatak i R8 je alifatski ili heteroalifatski ostatak.
9. Farmaceutski pripravak za upotrebu prema bilo kojem od zahtjeva 1-3, naznačen time da umreženi aminski polimer sadrži ostatak amina koji odgovara formuli 2:
[image]
pri čemu
m i n su neovisno ne negativni cijeli brojevi;
R10, R20, R30 i R40 su neovisno vodik, hidrokarbil ili supstituirani hidrokarbil;
X1 je
[image]
X2 je hidrokarbil ili supstituirani hidrokarbil;
svaki X11 je neovisno vodik, hidrokarbil, supstituirani hidrokarbil, hidroksi ili amino; i
z je ne negativni broj.
10. Farmaceutski pripravak za upotrebu prema zahtjevu 9, naznačen time da R10, R20, R30 i R40 su neovisno vodik, alifatski, aril, heteroalifatski ostatak ili heteroaril, m i z su neovisno 0-3 i n je 0 ili 1, i/ili X2 je alifatski ili heteroalifatski ostatak.
11. Farmaceutski pripravak za upotrebu prema zahtjevu 9 ili 10, naznačen time da m je 1-3 i X11 je vodik, alifatski ili heteroalifatski ostatak.
12. Farmaceutski pripravak za upotrebu prema bilo kojem od zahtjeva 1-3, naznačen time da umreženi aminski polimer sadrži aminski ostatak koji odgovara formuli 2a:
[image]
pri čemu
m i n su neovisno ne negativni cijeli brojevi;
svaki R11 je neovisno vodik, hidrokarbil, heteroalifatski ili heteroaril;
R21 i R31 su neovisno vodik ili heteroalifatski ostatak;
R41 je vodik, supstituirani hidrokarbil ili hidrokarbil:
X1 je
[image]
X2 je alkil ili supstituirani hidrokarbil:
svaki X12 je neovisno vodik, hidroksi, amino, aminoalkil, boronska kiselina ili halo; i
z je ne negativni broj.
13. Farmaceutski pripravak za upotrebu prema zahtjevu 12, naznačen time da m i z su neovisno 0-3 i n je 0 ili 1.
14. Farmaceutski pripravak za upotrebu prema zahtjevu 12 ili 13, naznačen time da R11 je neovisno vodik, alifatski ostatak, aminoalkil, haloalkil, ili heteroaril, R21 i R31 su neovisno vodik ili heteroalifatski ostatak i R41 je vodik, alifatski, aril, heteroalifatski ostatak ili heteroaril ili određenije farmaceutski pripravak prema zahtjevu 12 ili 13 pri čemu svaki R11 je vodik, alifatski ostatak, aminoalkil ili haloalkil, R21 i R31 su vodik ili aminoalkil i R41 je vodik, alifatski ili heteroalifatski ostatak.
15. Farmaceutski pripravak za upotrebu prema zahtjevu 1-3, naznačen time da umreženi aminski polimer sadrži aminski ostatak koji odgovara formuli 2b:
[image]
pri čemu
m i n su neovisno ne negativni cijeli brojevi;
svaki R12 je neovisno vodik, supstituirani hidrokarbil ili hidrokarbil;
R22 i R32 su neovisno vodik, supstituirani hidrokarbil ili hidrokarbil;
R42 je vodik, hidrokarbil ili supstituirani hidrokarbil;
X1 je
[image]
X2 je alkil, aminoalkil ili alkanoil;
svaki X13 je neovisno vodik, hidroksi, aliciklički ostatak, amino, aminoalkil, halogen, heteroaril, boronska kiselina ili aril;
z je ne negativni broj; i
amin koji odgovara formuli 2b sadrži najmanje jednu alil skupinu.
16. Farmaceutski pripravak za upotrebu prema zahtjevu 15, naznačen time da m i z su neovisno 0-3 i n je 0 ili 1.
17. Farmaceutski pripravak za upotrebu prema zahtjevu 15 ili 16, naznačen time da R12 ili R42 neovisno sadrže najmanje jedan alil ili vinil ostatak, ili farmaceutski pripravak prema zahtjevu 15 ili 16 pri čemu (i) m je pozitivni cijeli broj i R12, R22 i R42 u kombinaciji sadrže najmanje dva alil ili vinil ostatka ili (ii) n je pozitivan cijeli broj i R12, R22 i R42 u kombinaciji, sadrži najmanje dva alil ili vinil ostatka.
18. Farmaceutski pripravak za upotrebu prema bilo kojem od prethodnih zahtjeva, naznačen time da umreženi aminski polimer ima odgovarajući molarni omjer vezanja kloridnog iona prema fosfatnom od najmanje 0,5 : 1, u vodenom neorganskom puferu koji simulira tanko crijevo ("SIB") koji sadrži 36 mM NaCl, 20 mM NaH2PO4, i 50 mM 2-(N-morfolino)etansulfonske kiseline (MES) puferiran na pH 5,5 i na 37 °C.
19. Farmaceutski pripravak za upotrebu prema bilo kojem od prethodnih zahtjeva, naznačen time da umreženi aminski polimer ima odgovarajući molarni omjer vezanja kloridnog iona prema fosfatnom od najmanje 1:1, u vodenom neorganskom puferu koji simulira tanko crijevo ("SIB") koji sadrži 36 mM NaCl, 20 mM NaH2PO4, i 50 mM 2-(N-morfolino)etansulfonske kiseline (MES) puferiran na pH 5,5 i na 37 °C.
20. Farmaceutski pripravak za upotrebu prema bilo kojem od prethodnih zahtjeva naznačen time da umreženi aminski polimer ima odgovarajući molarni omjer vezanja kloridnog iona prema fosfatnom od najmanje 2:1, u vodenom neorganskom puferu koji simulira tanko crijevo ("SIB") koji sadrži 36 mM NaCl, 20 mM NaH2PO4, i 50 mM 2-(N-morfolino)etansulfonske kiseline (MES) puferiran na pH 5,5 i na 37 °C.
21. Farmaceutski pripravak za upotrebu prema bilo kojem od prethodnih zahtjeva naznačen time da umreženi aminski polimer ima kapacitet vezanja protona od najmanje 10 mmol/g i kapacitet vezanja kloridnog iona od najmanje 10 mmol/g u vodenom puferu koji simulira želučanu tekućinu ("SGF") koji sadrži 35 mM NaCl i 63 mM HCl na pH 1,2 i 37 °C.
22. Farmaceutski pripravak za upotrebu prema bilo kojem od prethodnih zahtjeva naznačen time da umreženi aminski polimer ima ravnotežni kapacitet vezanja protona od najmanje 12 mmol/g i kapacitet vezanja kloridnog iona od najmanje 12 mmol/g , ili ravnotežni kapacitet vezanja protona od najmanje 14 mmol/g i kapacitet vezanja kloridnog iona od najmanje 14 mmol/g u vodenom puferu koji simulira želučanu tekućinu ("SGF") koji sadrži 35 mM NaCl i 63 mM HCl na pH 1,2 i 37 °C.
23. Farmaceutski pripravak za upotrebu prema bilo kojem prethodnom zahtjevu naznačen time da je vezanje klorida u SIB testu nakon jednog sata izlaganja polimera testnom puferu na 37 °C veće od 2,0 mmol po gramu polimera, ili veće od 2,5 mmol/g polimera, ili veće od 3,0 mmol/g polimera, ili veće od 3,5 mmol/g polimera ili veće od 4,00 mmol/g polimera.
24. Farmaceutski pripravak za upotrebu prema bilo kojem prethodnom zahtjevu, naznačen time da se primjenjuje manje od 1 g, 0,5 g ili 0,1 natrija ili kalija dnevno, ili pri čemu se ne daje natrij ili kalij.
25. Farmaceutski pripravak za upotrebu prema bilo kojem prethodnom zahtjevu, naznačen time da je primijenjena dnevna doza manja od 20 g, ili manja od 15 g, ili manja od 10 g, ili manja od 5 g, ili manja od 4 g ,ili manja od 3 g.
26. Farmaceutski pripravak za upotrebu prema bilo kojem prethodnom zahtjevu, naznačen time da se dnevna doza daje jednom dnevno, ili dva puta dnevno ili tri puta dnevno.
27. Farmaceutski pripravak za upotrebu prema bilo kojem prethodnom zahtjevu naznačen time da je metabolička acidoza kronična metabolička acidoza.
28. Farmaceutski pripravak za upotrebu prema bilo kojem prethodnom zahtjevu naznačen time da dnevna doza dovodi do održanog porasta bikarbonata u serumu od ≥1,6 mEq/L, ili ≥2 mEq/L, ili ≥3 mEq/L, ili ≥5 mEq/L, ili ≥10 mEq/L.
29. Farmaceutski pripravak za upotrebu prema bilo kojem prethodnom zahtjevu, naznačen time da je u navedenom postupku doza titrirana na osnovi vrijednosti bikarbonata u serumu pacijenta kojem je potrebno liječenje ili drugim indikatorima acidoze.
30. Farmaceutski pripravak za upotrebu prema bilo kojem prethodnom zahtjevu, gdje je metabolička acidoza naznačena time što je vrijednost bikarbonata u serumu manja od 22 mEq/L.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361831445P | 2013-06-05 | 2013-06-05 | |
| PCT/US2014/041152 WO2014197725A1 (en) | 2013-06-05 | 2014-06-05 | Proton-binding polymers for oral administration |
| EP14742001.2A EP3003327B1 (en) | 2013-06-05 | 2014-06-05 | Proton-binding polymers for oral administration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171590T1 true HRP20171590T1 (hr) | 2017-12-29 |
Family
ID=51212941
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171590TT HRP20171590T1 (hr) | 2013-06-05 | 2017-10-18 | Polimeri koji vežu protone za oralnu primjenu |
| HRP20191074TT HRP20191074T1 (hr) | 2013-06-05 | 2019-06-14 | Polimeri koji vežu protone za oralnu primjenu |
| HRP20201767TT HRP20201767T1 (hr) | 2013-06-05 | 2020-11-02 | Polimeri koji vežu protone za oralnu primjenu |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191074TT HRP20191074T1 (hr) | 2013-06-05 | 2019-06-14 | Polimeri koji vežu protone za oralnu primjenu |
| HRP20201767TT HRP20201767T1 (hr) | 2013-06-05 | 2020-11-02 | Polimeri koji vežu protone za oralnu primjenu |
Country Status (25)
| Country | Link |
|---|---|
| US (8) | US9205107B2 (hr) |
| EP (4) | EP3812761A1 (hr) |
| JP (4) | JP6453860B2 (hr) |
| KR (4) | KR102318910B1 (hr) |
| CN (3) | CN105377270B (hr) |
| AU (3) | AU2014274817B2 (hr) |
| BR (1) | BR112015030142B1 (hr) |
| CA (1) | CA2912911C (hr) |
| CY (3) | CY1119611T1 (hr) |
| DK (3) | DK3578185T3 (hr) |
| ES (3) | ES2733493T3 (hr) |
| HK (3) | HK1222120A1 (hr) |
| HR (3) | HRP20171590T1 (hr) |
| HU (3) | HUE043999T2 (hr) |
| IL (3) | IL242758B (hr) |
| LT (3) | LT3003327T (hr) |
| MX (3) | MX364785B (hr) |
| NO (1) | NO2905572T3 (hr) |
| PL (2) | PL3003327T3 (hr) |
| PT (3) | PT3287133T (hr) |
| RS (2) | RS61005B1 (hr) |
| RU (1) | RU2728778C2 (hr) |
| SI (3) | SI3287133T1 (hr) |
| TR (1) | TR201909355T4 (hr) |
| WO (1) | WO2014197725A1 (hr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014274817B2 (en) * | 2013-06-05 | 2019-05-23 | Tricida, Inc. | Proton-binding polymers for oral administration |
| ES2857177T3 (es) | 2014-12-10 | 2021-09-28 | Tricida Inc | Polímeros de unión de protones para administración oral |
| SG11201809605PA (en) * | 2016-05-06 | 2018-11-29 | Tricida Inc | Compositions for and method of treating acid-base disorders |
| WO2018124264A1 (ja) | 2016-12-28 | 2018-07-05 | 富士フイルム株式会社 | 窒素原子含有ポリマー又はその塩の乳化液、その製造方法、及び粒子の製造方法 |
| US10934380B1 (en) | 2017-09-25 | 2021-03-02 | Tricida, Inc. | Crosslinked poly(allylamine) polymer pharmaceutical compositions |
| TW201922267A (zh) | 2017-10-16 | 2019-06-16 | 日商富士軟片股份有限公司 | 高磷血症治療劑 |
| US20210187011A1 (en) * | 2017-11-03 | 2021-06-24 | Tricida, Inc. | Method of treating acid-base disorders |
| SG11202003451UA (en) | 2017-11-03 | 2020-05-28 | Tricida Inc | Compositions for and method of treating acid-base disorders |
| WO2019236636A1 (en) * | 2018-06-04 | 2019-12-12 | Tricida, Inc. | Method of treating acid-base disorders |
| JP2022540707A (ja) * | 2019-07-19 | 2022-09-16 | アカテコール・インコーポレイテッド | 分子的に十分に規定された生物付着防止ポリイオンコーティング |
| EP4053179A1 (en) | 2021-03-01 | 2022-09-07 | Tricida Inc. | Crosslinked poly(allylamine) polymer pharmaceutical compositions |
| WO2023109825A1 (zh) * | 2021-12-14 | 2023-06-22 | 上海石趣医药科技有限公司 | 氧化银和/或其水合物在制备药物中的用途 |
| CN115260355A (zh) * | 2022-05-16 | 2022-11-01 | 江苏中天药业有限公司 | 一种阴离子交换树脂、其制备方法、该树脂与药物的复合物和其掩味制剂 |
| KR20230047972A (ko) | 2023-03-21 | 2023-04-10 | 최문수 | 개인별 맞춤형 그립 형상이 형성된 운동기구용 손잡이 |
Family Cites Families (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050090553A1 (en) | 1992-06-30 | 2005-04-28 | Shapiro Howard K. | Compositions and method for treatment of chronic inflammatory diseases |
| US6444221B1 (en) | 1992-06-30 | 2002-09-03 | Howard K. Shapiro | Methods of treating chronic inflammatory diseases using carbonyl trapping agents |
| CA2202397C (en) | 1994-10-17 | 2002-07-16 | Peter W. Stacpoole | Compositions comprising carbonate/bicarbonate buffered dichloroacetic acid and methods for treatment of metabolic and cardiovascular disorders |
| US5534259A (en) * | 1993-07-08 | 1996-07-09 | Liposome Technology, Inc. | Polymer compound and coated particle composition |
| US5496545A (en) | 1993-08-11 | 1996-03-05 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
| US5667775A (en) | 1993-08-11 | 1997-09-16 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
| US5648355A (en) | 1994-02-09 | 1997-07-15 | Kos Pharmaceutical, Inc. | Method of treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin |
| TW474813B (en) | 1994-06-10 | 2002-02-01 | Geltex Pharma Inc | Alkylated composition for removing bile salts from a patient |
| US20020006899A1 (en) | 1998-10-06 | 2002-01-17 | Pospisilik Andrew J. | Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals |
| US5753706A (en) | 1996-12-16 | 1998-05-19 | Hsu; Chen Hsing | Methods for treating renal failure |
| AUPO758297A0 (en) | 1997-06-27 | 1997-07-24 | Rowe, James Baber | Control of acidic gut syndrome |
| US6726905B1 (en) | 1997-11-05 | 2004-04-27 | Genzyme Corporation | Poly (diallylamines)-based phosphate binders |
| WO1999040990A1 (en) | 1998-02-17 | 1999-08-19 | University Of Maryland | Anion binding polymers and the use thereof |
| US6485703B1 (en) | 1998-07-31 | 2002-11-26 | The Texas A&M University System | Compositions and methods for analyte detection |
| US6271264B1 (en) | 1998-12-01 | 2001-08-07 | Geltex Pharmaceuticals, Inc. | Polymers containing spirobicyclic ammonium moieties as bile acid sequestrants |
| US6733780B1 (en) | 1999-10-19 | 2004-05-11 | Genzyme Corporation | Direct compression polymer tablet core |
| GB9927088D0 (en) | 1999-11-17 | 2000-01-12 | Secr Defence | Use of poly(diallylamine) polymers |
| US6844372B2 (en) | 2000-03-09 | 2005-01-18 | Hisamitsu Pharmaceutical Co., Inc. | Crosslinked anion-exchange resin or salt thereof and phosphorus adsorbent comprising the same |
| WO2001066606A1 (fr) | 2000-03-09 | 2001-09-13 | Hisamitsu Pharmaceutical Co., Inc. | Resine echangeuse d'anions reticulee ou sel de celle-ci |
| AU2001241095A1 (en) | 2000-03-13 | 2001-09-24 | Hisamitsu Pharmaceutical Co. Inc. | Preventives and/or remedies for hyperphosphatemia |
| JP2002028737A (ja) | 2000-07-07 | 2002-01-29 | Fujitsu Ltd | プレス打ち抜き加工方法及びプレス打ち抜き加工装置 |
| BR0209133A (pt) | 2001-04-18 | 2004-06-15 | Genzyme Corp | Método para tratar gota e para reduzir os nìveis de ácido úrico n0 sangue |
| BR0209020A (pt) * | 2001-04-18 | 2004-08-10 | Genzyme Corp | Composição farmacêutica de polialilamina |
| CN1274668C (zh) | 2002-03-11 | 2006-09-13 | 诺瓦提斯公司 | 那格列奈的盐 |
| US20070135335A1 (en) | 2003-02-10 | 2007-06-14 | Autogen Research Pty Ltd. | Therapeutic molecules |
| TWI335218B (en) | 2003-02-19 | 2011-01-01 | Panion & Bf Biotech Inc | Ferric organic compounds, uses thereof and methods of making same |
| CN1540136A (zh) * | 2003-10-27 | 2004-10-27 | 华东理工大学 | 一种评价微生物驱油能力的方法 |
| US7767768B2 (en) | 2003-11-03 | 2010-08-03 | Ilypsa, Inc. | Crosslinked amine polymers |
| US7385012B2 (en) | 2003-11-03 | 2008-06-10 | Ilypsa, Inc. | Polyamine polymers |
| US7335795B2 (en) | 2004-03-22 | 2008-02-26 | Ilypsa, Inc. | Crosslinked amine polymers |
| US7449605B2 (en) | 2003-11-03 | 2008-11-11 | Ilypsa, Inc. | Crosslinked amine polymers |
| US7608674B2 (en) * | 2003-11-03 | 2009-10-27 | Ilypsa, Inc. | Pharmaceutical compositions comprising cross-linked small molecule amine polymers |
| US7459502B2 (en) | 2003-11-03 | 2008-12-02 | Ilypsa, Inc. | Pharmaceutical compositions comprising crosslinked polyamine polymers |
| CA2551528A1 (en) | 2003-12-31 | 2005-07-21 | Genzyme Corporation | Enteric coated aliphatic amine polymer bile acid sequestrants |
| EP1723968A1 (en) | 2004-01-29 | 2006-11-22 | Keio University | Erythrocyte function modifying substance |
| US7854924B2 (en) | 2004-03-30 | 2010-12-21 | Relypsa, Inc. | Methods and compositions for treatment of ion imbalances |
| US8282960B2 (en) | 2004-03-30 | 2012-10-09 | Relypsa, Inc. | Ion binding compositions |
| JP5000480B2 (ja) | 2004-03-30 | 2012-08-15 | レリプサ， インコーポレイテッド | イオンバランス異常の治療の方法および組成物 |
| US7429394B2 (en) | 2004-03-30 | 2008-09-30 | Relypsa, Inc. | Ion binding compositions |
| US8192758B2 (en) | 2004-03-30 | 2012-06-05 | Relypsa, Inc. | Ion binding compositions |
| US7556799B2 (en) | 2004-03-30 | 2009-07-07 | Relypsa, Inc. | Ion binding polymers and uses thereof |
| US8399025B2 (en) | 2004-06-04 | 2013-03-19 | Board Of Regents, The University Of Texas System | Polyamine modified particles |
| CN101022821B (zh) | 2004-07-19 | 2014-01-29 | 纽崔西亚公司 | 天冬氨酸用于调节血中葡萄糖水平的用途 |
| DE102004035808A1 (de) | 2004-07-21 | 2006-03-16 | Kasch, Helmut, Dr. | Ammoniumsalze und Ammoniumsalz-Mineralsalzchlatrate als Transport- und Wirkform für pharmazeutische-medizinische und als Phasentransfermittel für chemische Anwendungen |
| US8569277B2 (en) | 2004-08-11 | 2013-10-29 | Palo Alto Investors | Methods of treating a subject for a condition |
| US20080214440A1 (en) | 2004-10-08 | 2008-09-04 | Forbes Medi-Tech (Research), Inc. | Vasoactive intestinal polypeptide compositions |
| US20070293429A1 (en) | 2004-10-08 | 2007-12-20 | Therapei Pharmaceuticals, Inc. | Vasoactive Intestinal Polypeptide Compositions |
| AU2005296290A1 (en) * | 2004-10-13 | 2006-04-27 | Ilypsa, Inc. | Crosslinked amine polymers |
| US7985418B2 (en) | 2004-11-01 | 2011-07-26 | Genzyme Corporation | Aliphatic amine polymer salts for tableting |
| ITME20040015A1 (it) | 2004-12-07 | 2005-03-07 | Vincenzo Savica | Chewing gum, caramelle gommose, pastiglie, compresse a lento rilascio di chelanti fosfato e/o fosforo salivare e capsule a lento rilascio di chelanti fosfato e/o fosforo a livello gastroenterico. |
| AU2006264407B2 (en) | 2005-07-04 | 2012-08-30 | Ramu Krishnan | Improved drug or pharmaceutical compounds and a preparation thereof |
| CA2619591C (en) | 2005-08-18 | 2020-03-24 | Globoasia, Llc | Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same |
| WO2007027566A2 (en) | 2005-09-02 | 2007-03-08 | Genzyme Corporation | Method for removing phosphate and polymer used therefore |
| WO2007038801A2 (en) | 2005-09-30 | 2007-04-05 | Ilypsa, Inc. | Monovalent cation-binding compositions comprising core-shell particles having crosslinked poly-vinylic shells, and methods of use thereof |
| CA2624170C (en) * | 2005-09-30 | 2014-02-25 | Ilypsa, Inc. | Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal |
| DE112006002617T5 (de) | 2005-09-30 | 2008-08-28 | Ilypsa Inc., Santa Clara | Verfahren zur Herstellung von Core-Shell-Kompositen bzw. Kern-Hüllen-Kompositen mit vernetzten Hüllen und daraus entstehende Core-Shell-Komposite |
| KR101119847B1 (ko) | 2005-11-08 | 2012-03-14 | 아지노모토 가부시키가이샤 | 마취 각성 촉진제 |
| BRPI0618352A2 (pt) | 2005-11-08 | 2011-08-23 | Genzyme Corp | composições farmacêuticas e métodos de tratamento da hiperfosfatemia em um paciente |
| ITMI20052461A1 (it) | 2005-12-22 | 2007-06-23 | Univ Degli Studi Milano | Sistemi microparticellari per la somministrazione orale di sostanze biologicamente attive |
| RU2008136081A (ru) | 2006-02-14 | 2010-03-20 | Тева Фармасьютикл Индастриес Лтд. (Il) | Фармацевтические составы с алифатическими аминными полимерами и способы их производства |
| US20080085259A1 (en) | 2006-05-05 | 2008-04-10 | Huval Chad C | Amine condensation polymers as phosphate sequestrants |
| JP2009542653A (ja) | 2006-07-05 | 2009-12-03 | ジェンザイム コーポレーション | リン酸塩過剰血症のための鉄（ｉｉ）含有治療剤 |
| MX2009000611A (es) | 2006-07-18 | 2009-04-16 | Genzyme Corp | Dendrimeros de amina. |
| CN101541235A (zh) * | 2006-07-18 | 2009-09-23 | 基酶有限公司 | 胺类树状物 |
| US8391873B2 (en) | 2006-07-21 | 2013-03-05 | Qualcomm Incorporated | Systems and methods for coordinating supplementary services for voice telephone calls in a centralized fashion |
| WO2008016729A1 (en) | 2006-08-04 | 2008-02-07 | Nastech Pharmaceutical Company Inc. | Compositions for intranasal delivery of human insulin and uses thereof |
| US7964182B2 (en) * | 2006-09-01 | 2011-06-21 | USV, Ltd | Pharmaceutical compositions comprising phosphate-binding polymer |
| EP2068819A4 (en) * | 2006-09-01 | 2011-04-20 | Genzyme Corp | Dendrimer COMPOSITIONS |
| RU2009111853A (ru) | 2006-09-01 | 2010-10-10 | Юсв Лимитед (In) | Способ получения гидрохлорида севеламера и его лекарственной формы |
| US7868045B2 (en) | 2006-09-06 | 2011-01-11 | Sucampo Ag | Method for promoting gastrointestinal bicarbonate secretion |
| BRPI0717545A2 (pt) | 2006-09-29 | 2013-10-22 | Gezyme Corp | Composição farmacêutica, método para tratar uma doença, polímero de amida, rede de polímero, e, método para preparar um polímero de amida |
| US8163799B2 (en) | 2006-12-14 | 2012-04-24 | Genzyme Corporation | Amido-amine polymer compositions |
| US20100129309A1 (en) | 2007-02-23 | 2010-05-27 | Dhal Pradeep K | Amine polymer compositions |
| US20080207766A1 (en) | 2007-02-27 | 2008-08-28 | Agi Therapeutics Research Ltd. | Methods and compositions for treating at least one upper gastrointestinal symptom |
| WO2008109095A1 (en) | 2007-03-08 | 2008-09-12 | Genzyme Corporation | Sulfone polymer compositions |
| TWI445540B (zh) | 2007-04-20 | 2014-07-21 | Ajinomoto Kk | 抗低體溫組成物 |
| US20100166696A1 (en) | 2007-04-27 | 2010-07-01 | Dhal Pradeep K | Amido-amine dendrimer compositions |
| WO2009005838A2 (en) | 2007-07-02 | 2009-01-08 | Cognate3 Llc | Process for the preparation of a non-corrosive base solution and methods of using same |
| KR20100045965A (ko) * | 2007-07-11 | 2010-05-04 | 도레이 카부시키가이샤 | 가교 폴리알릴아민 또는 그 산부가염 및 그 의약 용도 |
| EP2016947A1 (en) | 2007-07-17 | 2009-01-21 | Chemo Ibérica, S.A. | Novel one step process for preparing cross-linked poly(allylamine) polymers |
| WO2009023544A2 (en) | 2007-08-10 | 2009-02-19 | Ilypsa, Inc. | Dosage unit anion-exchange polymer pharmaceutical compositions |
| US20090156647A1 (en) | 2007-12-12 | 2009-06-18 | Iovate T. & P. Inc. | Method for maintaining physiological pH levels during intensive physical exercise |
| PA8807201A1 (es) | 2007-12-14 | 2009-07-23 | Genzyme Corp | Composiciones farmaceuticas |
| JP2011506449A (ja) | 2007-12-14 | 2011-03-03 | ジェンザイム コーポレーション | コーティング医薬組成物 |
| WO2009097127A1 (en) | 2008-01-31 | 2009-08-06 | Genzyme Corporation | Pharmaceutical compositions |
| WO2009114650A1 (en) | 2008-03-11 | 2009-09-17 | Chakshu Research, Inc. | Methods and compositions for treating inflammation and inflammation-related pathologies |
| US20100331516A1 (en) | 2008-04-08 | 2010-12-30 | Govind Dhananjay Sathe | Process for Preparation of Sevelamer Carbonate |
| ES2380162T3 (es) | 2008-04-11 | 2012-05-09 | Gp Investimenti S.R.L. | Dispositivo de uso manual para el tratamiento de tejido humano con ultrasonidos |
| WO2009154747A1 (en) | 2008-06-20 | 2009-12-23 | Genzyme Corporation | Pharmaceutical compositions |
| DE102008030046A1 (de) | 2008-06-25 | 2009-12-31 | Ratiopharm Gmbh | Kompaktiertes Polyallylamin-Polymer |
| US20100008988A1 (en) | 2008-07-14 | 2010-01-14 | Glenmark Generics, Ltd. | Tablet compositions of amine polymers |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| US20100104527A1 (en) | 2008-08-22 | 2010-04-29 | Relypsa, Inc. | Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties |
| WO2010022380A2 (en) | 2008-08-22 | 2010-02-25 | Relypsa, Inc. | Linear polyol stabilized polyfluoroacrylate compositions |
| CA2737452C (en) | 2008-09-25 | 2018-05-22 | Vive Nano Inc. | Methods to produce polymer nanoparticles and formulations of active ingredients |
| WO2010035273A2 (en) | 2008-09-29 | 2010-04-01 | Intec Pharma Ltd. | Novel gastroretentive delivery system |
| WO2010059384A1 (en) | 2008-10-30 | 2010-05-27 | Janssen Pharmaceutica Nv | Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives useful as gdir agonists |
| US20100166861A1 (en) | 2008-12-29 | 2010-07-01 | Kelly Noel Lynch | Pharmaceutical formulations of sevalamer, or salts thereof, and copovidone |
| AU2010209293A1 (en) | 2009-01-22 | 2011-09-08 | Usv Limited | Pharmaceutical compositions comprising phosphate-binding polymer |
| US8945508B2 (en) | 2009-10-13 | 2015-02-03 | The Regents Of The University Of Michigan | Dendrimer compositions and methods of synthesis |
| DK2490675T3 (en) | 2009-10-22 | 2019-04-29 | Synthon Bv | Pharmaceutical compositions with sevelamer |
| WO2011071927A2 (en) | 2009-12-07 | 2011-06-16 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
| WO2011106542A2 (en) | 2010-02-24 | 2011-09-01 | Relypsa, Inc. | Crosslinked polyvrnylamine, poly all ylamine, and polyethyleneimine for use as bile acid sequestrants |
| AU2011220745B2 (en) | 2010-02-24 | 2016-12-01 | Relypsa, Inc. | Polyimidazoles for use as bile acid sequestrants |
| RU2417782C1 (ru) * | 2010-03-03 | 2011-05-10 | Федеральное государственное образовательное учреждение высшего профессионального образования "Белгородская государственная сельскохозяйственная академия" | Способ лечения ацидоза рубца |
| IT1406068B1 (it) | 2010-07-22 | 2014-02-06 | Medestea Int Spa | Polidesossiribonucleotidi (pdrn) per l'impiego nel trattamento di condizioni di acidosi e composizioni a base di polidesossiribonucleotidi per il suddetto impiego |
| US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
| KR101238210B1 (ko) | 2011-06-30 | 2013-03-04 | 엘지전자 주식회사 | 이동 단말기 |
| US20130137772A1 (en) | 2011-11-29 | 2013-05-30 | Raymond J. Bergeron | Hydroxypolyamine salts |
| EA201590062A1 (ru) | 2012-06-21 | 2016-02-29 | Керикс Байофармасьютикалз, Инк. | Применение лимонно-кислого железа при лечении пациентов с хронической почечной недостаточностью |
| CA2886788C (en) | 2012-10-08 | 2022-04-19 | Relypsa, Inc. | Potassium-binding agents for treating hypertension and hyperkalemia |
| AU2014274817B2 (en) | 2013-06-05 | 2019-05-23 | Tricida, Inc. | Proton-binding polymers for oral administration |
| BR112016009901A8 (pt) | 2013-11-04 | 2020-04-14 | Keryx Biopharmaceuticals Inc | uso de citrato férrico |
| ES2857177T3 (es) | 2014-12-10 | 2021-09-28 | Tricida Inc | Polímeros de unión de protones para administración oral |
| SG11201809605PA (en) | 2016-05-06 | 2018-11-29 | Tricida Inc | Compositions for and method of treating acid-base disorders |
| SG11202003451UA (en) | 2017-11-03 | 2020-05-28 | Tricida Inc | Compositions for and method of treating acid-base disorders |
| US20210187011A1 (en) | 2017-11-03 | 2021-06-24 | Tricida, Inc. | Method of treating acid-base disorders |
| WO2019236639A1 (en) | 2018-06-04 | 2019-12-12 | Tricida, Inc. | Method of treating acid-base disorders |
| WO2019236636A1 (en) | 2018-06-04 | 2019-12-12 | Tricida, Inc. | Method of treating acid-base disorders |
| WO2019236124A1 (en) | 2018-06-04 | 2019-12-12 | Tricida, Inc. | Method of treating acid-base disorders |
-
2014
- 2014-06-05 AU AU2014274817A patent/AU2014274817B2/en active Active
- 2014-06-05 PL PL14742001T patent/PL3003327T3/pl unknown
- 2014-06-05 ES ES17177221T patent/ES2733493T3/es active Active
- 2014-06-05 LT LTEP14742001.2T patent/LT3003327T/lt unknown
- 2014-06-05 SI SI201431241T patent/SI3287133T1/sl unknown
- 2014-06-05 KR KR1020157036999A patent/KR102318910B1/ko active IP Right Grant
- 2014-06-05 TR TR2019/09355T patent/TR201909355T4/tr unknown
- 2014-06-05 PT PT17177221T patent/PT3287133T/pt unknown
- 2014-06-05 RS RS20201307A patent/RS61005B1/sr unknown
- 2014-06-05 CN CN201480032395.1A patent/CN105377270B/zh active Active
- 2014-06-05 EP EP20183421.5A patent/EP3812761A1/en active Pending
- 2014-06-05 ES ES19169259T patent/ES2834485T3/es active Active
- 2014-06-05 HU HUE17177221A patent/HUE043999T2/hu unknown
- 2014-06-05 HU HUE14742001A patent/HUE034836T2/en unknown
- 2014-06-05 BR BR112015030142-8A patent/BR112015030142B1/pt active IP Right Grant
- 2014-06-05 DK DK19169259.9T patent/DK3578185T3/da active
- 2014-06-05 DK DK17177221.3T patent/DK3287133T3/da active
- 2014-06-05 PT PT147420012T patent/PT3003327T/pt unknown
- 2014-06-05 HU HUE19169259A patent/HUE051198T2/hu unknown
- 2014-06-05 RU RU2015155596A patent/RU2728778C2/ru active
- 2014-06-05 SI SI201430466T patent/SI3003327T1/en unknown
- 2014-06-05 DK DK14742001.2T patent/DK3003327T3/en active
- 2014-06-05 PL PL17177221T patent/PL3287133T3/pl unknown
- 2014-06-05 WO PCT/US2014/041152 patent/WO2014197725A1/en active Application Filing
- 2014-06-05 MX MX2015016527A patent/MX364785B/es active IP Right Grant
- 2014-06-05 SI SI201431698T patent/SI3578185T1/sl unknown
- 2014-06-05 LT LTEP19169259.9T patent/LT3578185T/lt unknown
- 2014-06-05 JP JP2016518006A patent/JP6453860B2/ja active Active
- 2014-06-05 KR KR1020247003745A patent/KR20240023672A/ko active Search and Examination
- 2014-06-05 EP EP17177221.3A patent/EP3287133B1/en active Active
- 2014-06-05 CN CN202010780604.8A patent/CN111671767B/zh active Active
- 2014-06-05 PT PT191692599T patent/PT3578185T/pt unknown
- 2014-06-05 RS RS20190806A patent/RS59033B1/sr unknown
- 2014-06-05 KR KR1020217034420A patent/KR20210131457A/ko not_active Application Discontinuation
- 2014-06-05 KR KR1020237024806A patent/KR102633597B1/ko active IP Right Grant
- 2014-06-05 CN CN202010780603.3A patent/CN111671766B/zh active Active
- 2014-06-05 ES ES14742001.2T patent/ES2646271T3/es active Active
- 2014-06-05 EP EP14742001.2A patent/EP3003327B1/en active Active
- 2014-06-05 LT LTEP17177221.3T patent/LT3287133T/lt unknown
- 2014-06-05 EP EP19169259.9A patent/EP3578185B1/en active Active
- 2014-06-05 CA CA2912911A patent/CA2912911C/en active Active
- 2014-06-23 US US14/311,852 patent/US9205107B2/en active Active
-
2015
- 2015-01-27 NO NO15000230A patent/NO2905572T3/no unknown
- 2015-11-18 US US14/944,844 patent/US9925214B2/en active Active
- 2015-11-24 IL IL242758A patent/IL242758B/en active IP Right Grant
- 2015-12-01 MX MX2021013880A patent/MX2021013880A/es unknown
- 2015-12-01 MX MX2019005300A patent/MX2019005300A/es unknown
-
2016
- 2016-08-30 HK HK16110308.8A patent/HK1222120A1/zh unknown
- 2016-10-05 HK HK16111588.7A patent/HK1223288A1/zh unknown
-
2017
- 2017-09-26 US US15/715,934 patent/US9993500B2/en active Active
- 2017-10-18 HR HRP20171590TT patent/HRP20171590T1/hr unknown
- 2017-11-06 CY CY20171101159T patent/CY1119611T1/el unknown
-
2018
- 2018-06-07 US US16/002,269 patent/US10363268B2/en active Active
- 2018-06-07 US US16/002,306 patent/US10391118B2/en active Active
- 2018-08-16 HK HK18110550.1A patent/HK1251151B/zh unknown
- 2018-12-13 JP JP2018233254A patent/JP6759316B2/ja active Active
-
2019
- 2019-04-04 US US16/375,843 patent/US10369169B1/en active Active
- 2019-06-14 HR HRP20191074TT patent/HRP20191074T1/hr unknown
- 2019-07-04 CY CY20191100694T patent/CY1121801T1/el unknown
- 2019-08-16 US US16/542,969 patent/US11197887B2/en active Active
- 2019-08-22 AU AU2019219800A patent/AU2019219800B1/en active Active
- 2019-12-04 AU AU2019275584A patent/AU2019275584B2/en active Active
-
2020
- 2020-01-09 IL IL271932A patent/IL271932B/en active IP Right Grant
- 2020-09-02 JP JP2020147224A patent/JP7075455B2/ja active Active
- 2020-10-20 IL IL278183A patent/IL278183B/en unknown
- 2020-10-30 CY CY20201101028T patent/CY1123673T1/el unknown
- 2020-11-02 HR HRP20201767TT patent/HRP20201767T1/hr unknown
-
2021
- 2021-12-09 US US17/546,339 patent/US20220096534A1/en active Pending
-
2022
- 2022-05-13 JP JP2022079329A patent/JP2022107004A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171590T1 (hr) | Polimeri koji vežu protone za oralnu primjenu | |
| RU2018142943A (ru) | Композиции для лечения нарушений кислотно-основного равновесия | |
| BRPI0517916B8 (pt) | comprimido compreendendo carbonato de sevelamer e cloreto de sódio, e, uso de um comprimido | |
| HRP20191114T1 (hr) | Kationski polimeri na bazi glikogena | |
| RS53391B (en) | COPD COMBINED THERAPY (CHRONIC OBSTRUCTIVE LUNG DISEASES) | |
| BR112015025716A2 (pt) | pró-fármacos de nucleosídeo submetidos a deutério úteis para o tratamento de hcv | |
| MD4516C1 (ro) | Derivaţi noi de tienopirimidină, procedeu de preparare a acestora, compoziţii farmaceutice care îi conţin şi utilizările lor în calitate de agenţi proapoptotici | |
| CY1116143T1 (el) | Παραγωγα χρωμενονης με αντικαρκινικη δραση | |
| NZ629468A (en) | Tamper resistant immediate release formulations | |
| JP2016520652A5 (hr) | ||
| UY33605A (es) | Profarmacos que comprenden un conjugado de conector de exendina | |
| NZ609719A (en) | Pharmaceutical composition | |
| JP2009502355A5 (hr) | ||
| AR072652A1 (es) | Composicion farmaceutica que comprende un polimero de amina reticulada. comprimido. metodo de preparacion. metodo para tratar la hiperfosfatemia. | |
| BR0209133A (pt) | Método para tratar gota e para reduzir os nìveis de ácido úrico n0 sangue | |
| BR112012030398A2 (pt) | polímero espessado | |
| BR112017011838B1 (pt) | Polímeros de ligação a prótons para administração oral | |
| RU2010104673A (ru) | Сшитый полиаллиламин или его соль присоединения кислоты и его применение для медицинских целей | |
| GB201017889D0 (en) | A polymeric nanoparticle | |
| EA201591568A1 (ru) | Пероральная таблетированная фармацевтическая композиция двойного применения на основе сульфатных солей и способы ее применения | |
| BR112017013264A2 (pt) | ?sal de cálcio de um polímero de aglutinação de potássio reticulado, polímero de aglutinação de potássio reticulado, composição farmacêutica, e, método para remover potássio do trato gastrointestinal de um paciente?. | |
| HRP20230989T1 (hr) | Novi sastavi željeza i metode njihove izrade i upotrebe | |
| CN107802602B (zh) | 醋酸棉酚海藻酸钙凝胶微球的制备方法 | |
| BR112015003733A2 (pt) | composições de liberação estendida de um nitrato de aminoalquila | |
| JP2015528509A5 (hr) |